H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 79 Citations 21,847 235 World Ranking 686 National Ranking 4
Medicine D-index 88 Citations 25,295 311 World Ranking 6567 National Ranking 83

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Immune system
  • Gene

His primary areas of study are Immunology, Immunotherapy, Immune system, Cancer research and Cancer immunotherapy. His Immunology research includes elements of Cytotoxic T cell, Internal medicine and Cell culture. His Immunotherapy study combines topics from a wide range of disciplines, such as T cell, Immunity and Vaccination.

His Immune system research incorporates elements of Lymphocyte, Receptor, Antibody and Antigen. His Cancer research research is multidisciplinary, relying on both CD86 and Interleukin 8. Cancer covers Ignacio Melero research in Cancer immunotherapy.

His most cited work include:

  • Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (1507 citations)
  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (515 citations)
  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (515 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Immunology, Immunotherapy, Cancer research, Immune system and Internal medicine. Ignacio Melero has researched Immunology in several fields, including Interleukin 12 and Genetic enhancement. He studies Cancer immunotherapy, a branch of Immunotherapy.

His Cancer research research includes themes of Immunogenic cell death, Cytotoxic T cell, Cell culture and CD8. The Immune system study combines topics in areas such as Antibody and CD40. His work on Nivolumab, Hepatocellular carcinoma and Sorafenib as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.

He most often published in these fields:

  • Immunology (47.07%)
  • Immunotherapy (39.19%)
  • Cancer research (36.90%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (36.90%)
  • Immunotherapy (39.19%)
  • Immune system (29.01%)

In recent papers he was focusing on the following fields of study:

Ignacio Melero focuses on Cancer research, Immunotherapy, Immune system, Internal medicine and Cancer immunotherapy. His Cancer research study combines topics in areas such as Cytotoxic T cell, CD8, Antigen and Monoclonal antibody. Immunotherapy is a primary field of his research addressed under Immunology.

In the subject of general Immune system, his work in Immunity is often linked to Attenuated vaccine, thereby combining diverse domains of study. His Internal medicine research focuses on Oncology and how it relates to Atezolizumab, Chemotherapy, Inflammation and Phases of clinical research. His work deals with themes such as T cell, Adoptive cell transfer, Chimeric antigen receptor, Receptor and Interleukin 12, which intersect with Cancer immunotherapy.

Between 2018 and 2021, his most popular works were:

  • Dendritic cells in cancer immunology and immunotherapy. (256 citations)
  • Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. (179 citations)
  • Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 (179 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Immune system
  • Gene

Ignacio Melero mostly deals with Cancer research, Immune system, Immunotherapy, Cancer immunotherapy and Cancer. His Cancer research study incorporates themes from Immune checkpoint, CD137, Cytotoxic T cell, Monoclonal antibody and Immunogenic cell death. Ignacio Melero does research in Immune system, focusing on Tumor microenvironment specifically.

His Immunotherapy research incorporates themes from Colitis, Radioimmunotherapy, Melanoma, Lung cancer and Radiation therapy. His Cancer immunotherapy research is multidisciplinary, relying on both T cell, CTLA-4, Chimeric antigen receptor, Adoptive cell transfer and Antigen. The subject of his Antigen research is within the realm of Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry;Bruno Sangro;Thomas Yau;Todd S. Crocenzi.
The Lancet (2017)

1976 Citations

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui.
Journal of Hepatology (2013)

675 Citations

Therapeutic vaccines for cancer: an overview of clinical trials

Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber.
Nature Reviews Clinical Oncology (2014)

604 Citations

Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors

Bruno Sangro;Guillermo Mazzolini;Juan Ruiz;Maite Herraiz.
Journal of Clinical Oncology (2004)

523 Citations

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Ignacio Melero;David M. Berman;M. Angela Aznar;Alan J. Korman.
Nature Reviews Cancer (2015)

504 Citations

Direct Effects of Type I Interferons on Cells of the Immune System

Sandra Hervas-Stubbs;Jose Luis Perez-Gracia;Ana Rouzaut;Miguel Fernandez de Sanmamed.
Clinical Cancer Research (2011)

422 Citations

Immunological landscape and immunotherapy of hepatocellular carcinoma

Jesús Prieto;Ignacio Melero;Bruno Sangro.
Nature Reviews Gastroenterology & Hepatology (2015)

372 Citations

Classification of current anticancer immunotherapies

Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué.
Oncotarget (2014)

340 Citations

CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

Noelia Casares;Laura Arribillaga;Pablo Sarobe;Javier Dotor.
Journal of Immunology (2003)

294 Citations

Dendritic cells in cancer immunology and immunotherapy.

Stefanie K Wculek;Francisco J Cueto;Adriana M Mujal;Adriana M Mujal;Ignacio Melero.
Nature Reviews Immunology (2020)

284 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ignacio Melero

Lorenzo Galluzzi

Lorenzo Galluzzi

Cornell University

Publications: 87

Jesús Prieto

Jesús Prieto

University of Navarra

Publications: 76

Guido Kroemer

Guido Kroemer

Sorbonne University

Publications: 68

Josep M. Llovet

Josep M. Llovet

Icahn School of Medicine at Mount Sinai

Publications: 65

Mark J. Smyth

Mark J. Smyth

QIMR Berghofer Medical Research Institute

Publications: 60

Masatoshi Kudo

Masatoshi Kudo

Kindai University

Publications: 55

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 53

Laurence Zitvogel

Laurence Zitvogel

Institut Gustave Roussy

Publications: 47

Tim F. Greten

Tim F. Greten

National Institutes of Health

Publications: 44

Jérôme Galon

Jérôme Galon

Université Paris Cité

Publications: 41

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 41

Phillip K. Darcy

Phillip K. Darcy

Peter MacCallum Cancer Centre

Publications: 36

Aurélien Marabelle

Aurélien Marabelle

Institut Gustave Roussy

Publications: 34

George Coukos

George Coukos

University of Lausanne

Publications: 33

Juan José Lasarte

Juan José Lasarte

University of Navarra

Publications: 33

Bruno Sangro

Bruno Sangro

University of Navarra

Publications: 31

Something went wrong. Please try again later.